在PD-1/PD-L1通路下治疗冠状动脉瘤的新进展

Jiawei Yin1, Peng Ren

  • 1Trauma Department of Orthopedics, The Second Hospital of Shandong University, Jinan, China.

概括

由于有限的治疗选择和对传统疗法的耐药性,冠状腺癌治疗仍然具有挑战性. 本综述探讨了编程细胞死亡蛋白-1 (PD-1) 和编程细胞死亡联体-1 (PD-L1) 阻断疗法的潜力,以改善冠状腺癌患者的治疗结果.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K